证券代码:002880 证券简称:卫光生物 公告编号:2025-041 深圳市卫光生物制品股份有限公司 关于参与竞拍国有建设用地使用权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年8月15日召开 第四届董事会第二次会议，审议通过了《关于拟参与竞拍国有建设用地使用权的 议案》，现将有关情况公告如下： 一、交易概述 根据公司发展战略规划，现有血液制品生产线进一步改造升级产能的空间极 其有限，公司急需新建工厂拓展产能。卫光生物智能产业基地项目已经公司于 2025年8月7日召开的2025年第二次临时股东会批准实施。根据深圳市国有建设用 地使用权出让公告（深土交告〔2025〕28号）公示的A628-0045宗地使用权相关 信息，公司将通过独立竞得用地方式取得该国有建设用地使用权。公司董事会授 权公司经营管理层全权办理与本次购买土地使用权有关的全部事宜（包括但不限 于在董事会审批权限范围内根据竞拍情况确定价格，并办理相关手续、签署相关 文件）。 （一）宗地代码：440311201007GB00106 （二 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-040 深圳市卫光生物制品股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）第四届董事会第二次会 议于2025年8月15日在公司办公楼四楼会议室以现场结合通讯方式召开。本次会 议应参加董事9名，实际参加董事9名，公司高级管理人员列席了会议。本次会议 由董事长张战先生主持，会议的召集、召开和表决程序符合《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）等有关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 会议经审议，书面表决，审议通过了以下议案： 审议通过了《关于拟参与竞拍国有建设用地使用权的议案》。 公司董事会经审议同意公司参与竞拍深圳市国有建设用地使用权出让公告 （深土交告〔2025〕28号）公示的、位于深圳市光明区马田街道的相关国有建设 用地使用权，并授权公司经营管理层全权办理与本次购买土地使用权有关的全部 事宜（包括但不限于在董事会审批权限范围内 ...

Core Viewpoint - Weigao Bio (002880.SZ) announced the need for a new factory to expand production capacity due to limited upgrade potential of existing blood product production lines [1] Group 1 - The company has received approval for the construction of the Weigao Bio Intelligent Industrial Base project during the second extraordinary shareholders' meeting held on August 7, 2025 [1] - The company plans to acquire the state-owned construction land use rights through an independent bidding process [1] - The starting price for the land auction is set at RMB 60.4 million [1]

上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第二次临时股东会的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 1 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第二次临时股东会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生 物制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 年第 二次临时股东会（以下简称"本次股东会"），并根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范 性文件以及现行有效的《深圳市卫光生物制品股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，对本次股东会相关法律事项进行见证并出具本法律意见 书。公司 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-039 深圳市卫光生物制品股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会召开期间无否决议案的情况； 2.本次股东会未涉及变更以往股东会已通过议案的情况。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议：2025 年 8 月 7 日 14:30。 4.会议召集人：公司董事会。 5.会议的召集、召开符合《公司法》《上市公司股东会规则》《公司章程》等的 规定。 （二）会议出席情况 出席会议总体情况：公司总股本为 226,800,000 股，通过现场和网络参加本次会 议的股东及股东代表共计 140 名，代表公司有表决权的股份为 165,871,468 股，占公 司有表决权股份总数的 73.1356%。其中，中小投资者共计 138 名，代表公司有表决 权的股份 1,441,468 股，占公司股份总数的 0.6356%。 现场会议出席情况：参加本次股东会现场会议的股东及股东代理人共 2 名，代 表有 ...

Group 1 - The core viewpoint of the article emphasizes that Guangming District is rapidly becoming a new hub for technological innovation, industrial development, and investment entrepreneurship, supported by optimal policies and services [1][2]. - Guangming is accelerating the construction of a world-class science city and aims to establish a comprehensive national science center in the Greater Bay Area, focusing on a core area known as "One City, Three Districts" [1][2]. - The district has established 23 major technological innovation platforms, with significant advancements in synthetic biology, brain research, and materials genetics, and has attracted a high concentration of talent, including 59 academicians and over 19,000 various talents [1][2]. Group 2 - Guangming District is focusing on three main industrial directions: life and health, new generation information technology, and artificial intelligence, forming a "3+3+1" key industrial cluster [2]. - The district has gathered nine billion-level enterprises, 35 listed companies, and 1,921 enterprises above designated size, showcasing its industrial strength and innovation capabilities [2]. - A comprehensive and efficient technology finance support system is being established, including the creation of a national science center venture capital fund and various industry funds, to stimulate innovation and industrial vitality [2]. Group 3 - The article highlights a recent event where nearly 40 representatives from venture capital institutions and industry experts visited Guangming to explore its technological innovation landscape [4][5]. - The visit included a tour of the Weiguang Life Science Park, which focuses on the transformation of scientific achievements and houses over 40 enterprises and research institutions [5]. - The Guangming District's urban planning exhibition showcased its strategic vision for becoming a world-class science city, receiving positive feedback from visitors regarding its vibrant development and business environment [6].

Group 1 - A new scientific city, Guangming Science City, is emerging in the northern part of Shenzhen, covering an area of 99 square kilometers and aiming to become a world-class scientific city and a global center for industrial and technological innovation [1] - The 13th Venture Capital Conference included a visit to Guangming Science City, attended by nearly 40 representatives from venture capital institutions, startups, and industry experts [1] Group 2 - The first stop of the visiting delegation was the Weiguang Life Science Park, a specialized industrial park focusing on synthetic biology, which aims to transform scientific achievements into practical applications [2] - The park has over 40 resident companies and research institutions, including significant entities like Shenzhen Medical Academy and Shenzhen Bay Laboratory, showcasing Guangming's advancements in the biomedicine sector [2] - The delegation also visited Shenzhen University of Technology, a new research-oriented university set to be established in 2024, which focuses on basic research and cutting-edge technology [2] Group 3 - The delegation concluded their visit at the Guangming District Urban Planning Exhibition Hall, where they gained insights into the regional development blueprint and praised the integration of technology and urban development [3] - Guests expressed admiration for Guangming's vibrant development, strong industrial clusters, quality business environment, and efficient enterprise services, highlighting the district's proactive approach to technological innovation and urban integration [3]

Core Viewpoint - The company, Weiguang Biological, plans to significantly expand its production capacity in the blood products sector, aiming to increase its output to 1,200 tons, which is 1.85 times its current capacity, through a fundraising initiative of up to 1.5 billion yuan [1][4][6]. Group 1: Company Expansion Plans - Weiguang Biological's fundraising plan includes raising no more than 1.5 billion yuan, with 1.2 billion yuan allocated for the construction of an intelligent industrial base and 300 million yuan for working capital [1][4]. - The total investment for the intelligent industrial base project is estimated at 2.308 billion yuan, with a construction period of 4.5 years [5][6]. - The company aims to produce various blood products, including human albumin and immunoglobulin, with the new facility expected to enhance its product offerings [6][17]. Group 2: Industry Context - The blood products industry is experiencing a wave of expansion, with several leading companies already establishing or constructing large-scale production bases [3][16]. - The demand for blood products is anticipated to grow due to an aging population and improved healthcare conditions, with the market projected to reach approximately 60 billion yuan in 2024 and 95 billion yuan by 2030 [9][10]. - The industry is characterized by a supply-demand imbalance, with domestic consumption of blood products still lagging behind international levels [8][10]. Group 3: Financial Challenges - The company faces a funding gap of 1.108 billion yuan even after the planned fundraising, as its current cash reserves are insufficient to meet investment needs [27][29]. - Weiguang Biological's asset-liability ratio stands at 30.47%, significantly higher than the industry average, which raises concerns about its financial stability [30][32]. - The company has experienced a slight decline in revenue and net profit in the first quarter of 2025, indicating potential financial pressures amid its expansion efforts [32].

Core Viewpoint - The company, Weigao Biologics, aims to enhance its production capacity and competitiveness in the increasingly concentrated domestic blood products industry by leveraging capital market resources through a private placement plan to raise up to 1.5 billion yuan [1][4]. Group 1: Capital Increase and Investment Plans - Weigao Biologics plans to issue no more than 45.36 million shares to raise up to 1.5 billion yuan, which will be allocated to the construction of an intelligent industrial base and to supplement working capital [1][2]. - The intelligent industrial base project is designed to have an annual processing capacity of 1,200 tons of blood plasma, with a total investment of 2.308 billion yuan, of which the company intends to invest no more than 1.2 billion yuan from the raised funds [2][3]. Group 2: Production Capacity and Market Position - The company’s existing blood product production line, built in 2013, has a current capacity of 650 tons, which is insufficient for future product development, necessitating the construction of a new factory [3][4]. - Weigao Biologics has seen its plasma collection volume grow from 466.77 tons in 2022 to 561.57 tons in 2024, with a compound annual growth rate of 9.69% [5]. - The company currently has 11 products in the market and plans to continue launching new products over the next five years, indicating a strong pipeline for future growth [3][5]. Group 3: Industry Context and Competitive Landscape - The blood products industry in China has around 30 companies, most of which are small and have limited product offerings, leading to low industry concentration [4]. - Major players in the industry are expanding their production capabilities through mergers and acquisitions, as well as building large-scale production bases, which Weigao Biologics is also pursuing [4][5]. - The company is actively expanding its plasma collection stations and enhancing the efficiency of existing ones to further increase its plasma collection volume [5].

Core Viewpoint - Weigao Biologics has reinitiated a private placement plan to increase production capacity, proposing to raise 1.5 billion yuan to build a new blood product factory, amid a rapidly consolidating industry landscape [1][6][7]. Company Summary - Weigao Biologics plans to issue up to 45.36 million shares to specific investors, with 1.2 billion yuan allocated for a new factory capable of processing 1,200 tons of plasma annually [1][4]. - The company previously attempted a private placement in 2022 for 1.15 billion yuan, which was approved but ultimately not executed due to market conditions [5][6]. - Current production lines, established in 2013, have limited capacity for further upgrades, with existing annual processing capacity only reaching 650 tons [5][6]. Industry Summary - The blood product industry is experiencing accelerated consolidation, with major players like Tian Tan Biologics and Shanghai Raist forming a leading group with over 1,000 tons of production capacity [1][6][7]. - Weigao Biologics faces increasing pressure as it aims to become the only company in South China with a production capacity of 1,000 tons, highlighting the urgency for differentiation in a competitive market [6][7]. - The industry is still in its early stages of consolidation, with significant competition expected to intensify as larger companies strengthen their market positions [7].